Phenothiazine compounds of Formula (I) are described herein. These compounds are useful as highly reducing organic photoredox catalysts. Suitable substrates for use with the compounds of Formula (I) include acrylates, styrene, acrylamides, acrylonitrile, vinyl chloride, methylacrylonitrile, vinyl acetate, and acrylic acid.

Phenothiazine compounds of Formula (I) are described herein. These compounds are useful as highly reducing organic photoredox catalysts. Suitable substrates for use with the compounds of Formula (I) include acrylates, styrene, acrylamides, acrylonitrile, vinyl chloride, methylacrylonitrile, vinyl acetate, and acrylic acid.

The present invention relates to compounds of the following general formula (I) or (II): or a pharmaceutically acceptable salt and/or solvate thereof, for use in the treatment and/or in the prevention of ErbB2 dependent cancers, and pharmaceutical compositions containing such compounds. ##STR00001##

The present invention relates to compounds of the following general formula (I) or (II): or a pharmaceutically acceptable salt and/or solvate thereof, for use in the treatment and/or in the prevention of ErbB2 dependent cancers, and pharmaceutical compositions containing such compounds. ##STR00001##

Phenothiazine compounds of Formula (I) are described herein. These compounds are useful as highly reducing organic photoredox catalysts. Suitable substrates for use with the compounds of Formula (I) include acrylates, styrene, acrylamides, acrylonitrile, vinyl chloride, methylacrylonitrile, vinyl acetate, and acrylic acid.

Phenothiazine compounds of Formula (I) are described herein. These compounds are useful as highly reducing organic photoredox catalysts. Suitable substrates for use with the compounds of Formula (I) include acrylates, styrene, acrylamides, acrylonitrile, vinyl chloride, methylacrylonitrile, vinyl acetate, and acrylic acid.

Compounds exhibiting high hole mobility and/or high glass transition temperatures are provided which are of the formula [Ar.sup.1].sub.m[Ar.sup.2].sub.n wherein: m is an integer from 1-3 and n is an integer and may be 1 or 2; Ar.sup.1 represents a thianthrene residue having a linkage to Ar.sup.2 at one or two positions selected from ring positions 1-4 and 5-8 and optionally mono-, bi- or poly-substituted with C.sub.1-C.sub.4-alkyl-, C.sub.1-C.sub.4-alkoxy-, fluoro, phenyl or biphenyl which in the case of phenyl or biphenyl may be further substituted with C.sub.1-C.sub.4-alkyl-, C.sub.1-C.sub.4-alkoxy- or fluoro; Ar.sup.2 represents a residue derived from an arylamine in which the aryl rings are phenyl, naphthyl or anthracenyl optionally substituted with C.sub.1-C.sub.4-alkyl, C.sub.1-C.sub.4-alkoxy- or fluoro, a polycyclic fused or chain aromatic ring system optionally containing nitrogen or sulphur and in a chain aromatic ring system optionally containing one or more chain oxygen or sulphur atoms, a triarylphosphine oxide or an arylsilane the rings of any of which are optionally substituted with C.sub.1-C.sub.4-alkyl-, C.sub.1-C.sub.4-alkoxy- or fluoro.

Certain of the compounds may be used in electron transport layers and may be doped with p-type dopants. They may be incorporated into OLEDs, organic photovoltaic devices, imaging members and thin film transistors.

In further embodiments there are provided OLEDs or other devices e.g. electrostatic latent image forming members in which improved efficiency is obtained by using as electron transport layers, electron injectors, hosts and emitters (dopants) ambipolar or electron-transmitting compounds in which thianthrene is bonded to aryl e.g. 1-anthracenyl-9-yl-thianthrene, 1-biphenyl-4-yl-thianthrene and 9,10-Bis(1-thianthrenyl) anthracene.

Compounds exhibiting high hole mobility and/or high glass transition temperatures are provided which are of the formula [Ar.sup.1].sub.m[Ar.sup.2].sub.n wherein: m is an integer from 1-3 and n is an integer and may be 1 or 2; Ar.sup.1 represents a thianthrene residue having a linkage to Ar.sup.2 at one or two positions selected from ring positions 1-4 and 5-8 and optionally mono-, bi- or poly-substituted with C.sub.1-C.sub.4-alkyl-, C.sub.1-C.sub.4-alkoxy-, fluoro, phenyl or biphenyl which in the case of phenyl or biphenyl may be further substituted with C.sub.1-C.sub.4-alkyl-, C.sub.1-C.sub.4-alkoxy- or fluoro; Ar.sup.2 represents a residue derived from an arylamine in which the aryl rings are phenyl, naphthyl or anthracenyl optionally substituted with C.sub.1-C.sub.4-alkyl-, C.sub.1-C.sub.4-alkoxy- or fluoro, a polycyclic fused or chain aromatic ring system optionally containing nitrogen or sulphur and in a chain aromatic ring system optionally containing one or more chain oxygen or sulphur atoms, a triarylphosphine oxide or an arylsilane the rings of any of which are optionally substituted with C.sub.1-C.sub.4-alkyl-, C.sub.1-C.sub.4-alkoxy- or fluoro. Certain of the compounds may be used in electron transport layers and may be doped with p-type dopants. They may be incorporated into OLEDs, organic photovoltaic devices, imaging members and thin film transistors. In further embodiments there are provided OLEDs or other devices e.g. electrostatic latent image forming members in which improved efficiency is obtained by using as electron transport layers, electron injectors, hosts and emitters (dopants) ambipolar or electron-transmitting compounds in which thianthrene is bonded to aryl e.g. 1-anthracenyl-9-yl-thianthrene, 1-biphenyl-4-yl-thianthrene and 9,10-Bis(1-thianthrenyl) anthracene.

The present invention relates to compounds of the following general formula (I) or (II): or a pharmaceutically acceptable salt and/or solvate thereof, for use in the treatment and/or in the prevention of ErbB2 dependent cancers, and pharmaceutical compositions containing such compounds.

##STR00001##

The present invention relates to compounds of the following general formula (I) or (II): or a pharmaceutically acceptable salt and/or solvate thereof, for use in the treatment and/or in the prevention of ErbB2 dependent cancers, and pharmaceutical compositions containing such compounds.

##STR00001##